RS51318B - Varijante imunoglobulina i njihova upotreba - Google Patents

Varijante imunoglobulina i njihova upotreba

Info

Publication number
RS51318B
RS51318B YUP-2005/0467A YUP20050467A RS51318B RS 51318 B RS51318 B RS 51318B YU P20050467 A YUP20050467 A YU P20050467A RS 51318 B RS51318 B RS 51318B
Authority
RS
Serbia
Prior art keywords
antibody
antigen
binding fragment
use according
cells
Prior art date
Application number
YUP-2005/0467A
Other languages
English (en)
Serbian (sr)
Inventor
Leonard G. Presta
Camellia W. Adams
Andrew C. Chan
Craig W. Crowley
Henry B. Lowman
Gerald R. Nakamura
Original Assignee
Genentech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32685285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51318(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc. filed Critical Genentech Inc.
Publication of RS20050467A publication Critical patent/RS20050467A/sr
Publication of RS51318B publication Critical patent/RS51318B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
YUP-2005/0467A 2002-12-16 2003-12-16 Varijante imunoglobulina i njihova upotreba RS51318B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43411502P 2002-12-16 2002-12-16
US52616303P 2003-12-01 2003-12-01
PCT/US2003/040426 WO2004056312A2 (en) 2002-12-16 2003-12-16 Immunoglobulin variants and uses thereof

Publications (2)

Publication Number Publication Date
RS20050467A RS20050467A (sr) 2007-08-03
RS51318B true RS51318B (sr) 2010-12-31

Family

ID=32685285

Family Applications (2)

Application Number Title Priority Date Filing Date
YUP-2005/0467A RS51318B (sr) 2002-12-16 2003-12-16 Varijante imunoglobulina i njihova upotreba
RSP-2010/0366A RS20100366A (sr) 2002-12-16 2003-12-16 Varijante imunoglobulina i njihova upotreba

Family Applications After (1)

Application Number Title Priority Date Filing Date
RSP-2010/0366A RS20100366A (sr) 2002-12-16 2003-12-16 Varijante imunoglobulina i njihova upotreba

Country Status (35)

Country Link
US (7) US7799900B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (5) EP1944320A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP4351674B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR20070055625A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN103833854B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (3) AR042485A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE470675T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003301079C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2018C021I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BRPI0316779B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2507898C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2008003323A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (2) CR7875A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1110759T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60332957D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1572744T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2633311T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR18C1023I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1248731A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20050649B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (3) HUE035898T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL168754A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA27704A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05006511A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO338402B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ566907A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL212899B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1572744E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (2) RS51318B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2326127C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG2013036975A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI2289936T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TW201000132A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA89350C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004056312A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (1102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
EP2990054A1 (en) 1998-08-11 2016-03-02 Biogen Inc. Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
MXPA01004649A (es) * 1998-11-09 2002-05-06 Idec Pharma Corp Tratamiento con anticuerpo quimerico anti-cd20 para pacientes que reciben transplantes de medula osea o celulas madre de sangre periferica.
DK2055313T3 (en) 1998-11-09 2015-07-27 Biogen Inc Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HK1043312B (en) * 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
CN1373672A (zh) * 1999-07-12 2002-10-09 杰南技术公司 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DK1443961T3 (da) * 2001-10-25 2009-08-24 Genentech Inc Glycoprotein-sammensætninger
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040018573A1 (en) * 2002-04-18 2004-01-29 Power Scott D Production of functional antibodies in filamentous fungi
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
PT1613350E (pt) * 2003-04-09 2009-06-24 Genentech Inc Terapia de doença auto-imune num paciente com uma resposta inadequada a um inibidor de tnf-alfa
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
PL1631313T3 (pl) * 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
EA025962B1 (ru) 2003-11-05 2017-02-28 Роше Гликарт Аг АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
CA2561264A1 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
RU2396980C2 (ru) * 2004-06-04 2010-08-20 Дженентек, Инк. Способ лечения волчанки
AR049200A1 (es) * 2004-06-04 2006-07-05 Genentech Inc Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
EP1773391A4 (en) * 2004-06-25 2009-01-21 Medimmune Inc INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
BRPI0513100A (pt) * 2004-07-22 2007-10-23 Genentech Inc métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
KR20070100228A (ko) * 2004-10-05 2007-10-10 제넨테크, 인크. 혈관염의 치료 방법
SV2006002258A (es) * 2004-10-08 2006-09-19 Wyeth Corp Inmunoterapia de trastornos autoinmunes
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP2325207B1 (en) 2004-11-12 2017-03-15 Xencor, Inc. FC variants with altered binding to FCRN
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
HUE026688T2 (en) 2004-12-28 2016-07-28 Univ Di Genova Monoclonal antibody to NKG2A
EP1841454A4 (en) * 2005-01-13 2009-07-22 Genentech Inc PROCESSING METHOD
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
EP1877441A2 (en) * 2005-04-26 2008-01-16 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
JP2008545958A (ja) 2005-05-20 2008-12-18 ジェネンテック・インコーポレーテッド 自己免疫性疾患の被検体の生体試料の前処理
ZA200710496B (en) * 2005-06-02 2009-04-29 Astrazeneca Ab Antibodies directed to CD20 and used thereof
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
AU2006281978A1 (en) * 2005-08-12 2007-02-22 Garvan Institute Of Medical Research Phrophylactic and/or therapeutic method for treatment of autoimmune disease
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
MY149159A (en) * 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1952150B1 (en) 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
RU2426742C2 (ru) 2005-12-02 2011-08-20 Дженентек, Инк. Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
PT1973950E (pt) 2006-01-05 2014-12-29 Genentech Inc Anticorpos anti-epbh4 e métodos que os utilizam
SI1976884T1 (sl) 2006-01-20 2013-04-30 Genetech, Inc. Anti-efrinB2 protitelesa in postopki uporabe le teh
JPWO2007102200A1 (ja) * 2006-03-07 2009-07-23 国立大学法人大阪大学 抗ｃｄ２０モノクローナル抗体
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
RS53168B (sr) 2006-05-30 2014-06-30 Genentech Inc. Antitela i imunokonjugati i njihova upotreba
AR061246A1 (es) 2006-06-06 2008-08-13 Genentech Inc Anticuerpos anti- dill4 y metodos que los usan
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
KR101513498B1 (ko) 2006-06-30 2015-04-21 노보 노르디스크 에이/에스 항―ｎｋｇ2ａ 항체 및 이들의 용도
JP5605895B2 (ja) 2006-07-04 2014-10-15 ゲンマブ エー／エス Ｃｏｐｄを処置するためのｃｄ２０結合分子
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides
DK2046809T3 (en) 2006-07-19 2017-03-13 Univ Pennsylvania WSX-1 / IL-27 AS A TARGET OBJECTIVE FOR ANTI-INFLAMMATORY REACTIONS
CA2658557C (en) 2006-08-14 2015-12-01 Xencor, Inc. Optimized antibodies that target cd19
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
US7923011B2 (en) 2006-10-12 2011-04-12 Genentech, Inc. Antibodies to lymphotoxin-alpha
HUE034263T2 (en) 2006-10-27 2018-02-28 Genentech Inc Antibodies and immunoconjugates and their applications
HUE041957T2 (hu) 2006-12-01 2019-06-28 Novartis Ag Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US20100267933A1 (en) 2006-12-21 2010-10-21 Moya Wilson Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
ES2426158T3 (es) 2007-01-22 2013-10-21 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos
JP2010518115A (ja) 2007-02-09 2010-05-27 ジェネンテック， インコーポレイテッド 抗Ｒｏｂｏ４抗体およびそれらのための使用
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN103435696B (zh) * 2007-06-25 2016-10-12 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
SG188136A1 (en) * 2007-09-13 2013-03-28 Delenex Therapeutics Ag HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
CA2978687C (en) 2007-09-26 2020-02-18 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
ME02101B (me) 2007-10-30 2015-10-20 Genentech Inc Pročišćavanje antitijela hromatografijom izmjene katjona
DK2514436T3 (en) 2007-11-07 2018-03-12 Genentech Inc IL-22 FOR USE IN TREATMENT OF MICROBIAL DISEASES
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
BR122021010656B1 (pt) 2007-12-26 2022-07-19 Xencor, Inc Anticorpo anti-tnf e composição farmacêutica
AU2009207644A1 (en) 2008-01-24 2009-07-30 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
PT2268310T (pt) * 2008-03-25 2016-08-23 Roche Glycart Ag Uso de um anticorpo anti-cd20 do tipo ii com citotoxicidade celular acrescida dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não-hodgkin
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
NZ588554A (en) * 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) * 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
CN102112494A (zh) * 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
CA2729949A1 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
DK2848625T3 (da) 2008-08-14 2019-10-07 Genentech Inc Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
KR20110076918A (ko) 2008-09-10 2011-07-06 제넨테크, 인크. 단백질의 산화성 분해를 방지하기 위한 조성물 및 방법
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
ES2828721T3 (es) * 2008-10-14 2021-05-27 Genentech Inc Variantes de inmunoglobulina y usos de las mismas
CA2742990A1 (en) * 2008-11-17 2010-05-20 Genentech, Inc. Method and formulation for reducing aggregation of a macromolecule under physiological conditions
US8927249B2 (en) 2008-12-09 2015-01-06 Halozyme, Inc. Extended soluble PH20 polypeptides and uses thereof
DK2370561T3 (da) 2008-12-16 2019-10-21 Emd Millipore Corp Omrøringstankreaktor og fremgangsmåde
BRPI0923034A2 (pt) 2008-12-17 2015-12-15 Genentech Inc terapia de combinação para virus da hepatite c
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN102264759B (zh) 2008-12-23 2016-05-11 弗·哈夫曼-拉罗切有限公司 与蛋白a的结合改变的免疫球蛋白变体
CA2752286A1 (en) * 2009-02-16 2010-08-19 Biolex Therapeutics, Inc. Humanized anti-cd20 antibodies and methods of use
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
CN104788564A (zh) 2009-03-25 2015-07-22 健泰科生物技术公司 抗-fgfr3抗体及其使用方法
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
MX2011010168A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos, trivalentes.
WO2010129609A2 (en) * 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
AU2010248938B2 (en) * 2009-05-13 2014-12-11 Gliknik Inc. Methods of using immunoglobulin aggregates
EP2435476A4 (en) * 2009-05-27 2013-04-17 Synageva Biopharma Corp ANTIBODIES OBTAINED FROM BIRDS
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2013500993A (ja) 2009-07-31 2013-01-10 ジェネンテック， インコーポレイテッド Ｂｖ８アンタゴニスト又はｇ−ｃｓｆアンタゴニストを用いた腫瘍転移の阻害
BR112012003066A2 (pt) 2009-08-14 2016-11-16 Roche Glycart Ag uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
UY32870A (es) * 2009-09-01 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
RU2539112C2 (ru) 2009-09-03 2015-01-10 Дженентек, Инк. Способы лечения, диагностики и мониторинга ревматоидного артрита
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
IN2012DN01663A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-09-16 2015-06-05 Immunomedics Inc
WO2011034604A2 (en) 2009-09-17 2011-03-24 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
CA2775959A1 (en) * 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2011050188A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
KR101968766B1 (ko) 2009-11-05 2019-04-12 제넨테크, 인크. 이종 폴리펩티드의 분비를 위한 방법 및 조성물
RU2581812C2 (ru) * 2009-11-30 2016-04-20 Биотест Аг Гуманизированные антитела против il-10 для лечения системной красной волчанки (sle)
US8722615B2 (en) 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US8486397B2 (en) 2009-12-11 2013-07-16 Genentech, Inc. Anti-VEGF-C antibodies and methods using same
CN103068849B (zh) 2009-12-23 2016-04-06 霍夫曼-拉罗奇有限公司 抗Bv8抗体及其用途
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011119487A2 (en) 2010-03-22 2011-09-29 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
CN102906117B (zh) 2010-03-24 2016-04-06 霍夫曼-拉罗奇有限公司 抗lrp6抗体
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
CA2795544A1 (en) 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
CN102958538A (zh) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
CN104777301B (zh) 2010-05-10 2018-04-20 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及流感病毒的奥司他韦易感性的测定
LT2571532T (lt) 2010-05-14 2017-08-10 Abbvie Inc. Il-1 surišantys baltymai
KR101551295B1 (ko) 2010-05-17 2015-09-08 이엠디 밀리포어 코포레이션 생체분자 정제용 자극 반응성 중합체
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
RU2577986C2 (ru) 2010-06-18 2016-03-20 Дженентек, Инк. Антитела против axl и способы их применения
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
MX339666B (es) 2010-06-24 2016-06-03 Genentech Inc * Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
AU2011274528B2 (en) 2010-07-09 2015-04-23 Genentech, Inc. Anti-neuropilin antibodies and methods of use
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
EP2598530A2 (en) 2010-07-29 2013-06-05 Xencor, Inc. Antibodies with modified isoelectric points
CN103153341B (zh) 2010-08-03 2015-05-27 霍夫曼-拉罗奇有限公司 慢性淋巴细胞性白血病(cll)生物标志物
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2805564A1 (en) 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX2013001336A (es) 2010-08-13 2013-03-08 Roche Glycart Ag Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
AU2011288487B2 (en) 2010-08-13 2015-10-01 Roche Glycart Ag Anti-FAP antibodies and methods of use
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
CN103080132B (zh) 2010-08-25 2016-06-08 弗·哈夫曼-拉罗切有限公司 抗il-18r1的抗体及其用途
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
ES2641916T3 (es) 2010-08-31 2017-11-14 Genentech, Inc. Biomarcadores y métodos de tratamiento
SMT202200321T1 (it) 2010-10-01 2022-09-14 Modernatx Inc Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
KR101933197B1 (ko) 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
AU2011326564A1 (en) 2010-11-10 2013-05-09 Genentech, Inc. Methods and compositions for neural disease immunotherapy
AU2011343570B2 (en) 2010-12-16 2016-11-03 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
EP2651976A1 (en) 2010-12-16 2013-10-23 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
WO2012087962A2 (en) 2010-12-20 2012-06-28 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
MX2013007168A (es) 2010-12-22 2013-11-04 Genentech Inc Anticuerpo anti-pcsk9 y metodos de uso.
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2482074A1 (en) * 2011-01-27 2012-08-01 Medizinische Hochschule Hannover Methods and means for diagnosing vasculitis
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
US20120258073A1 (en) 2011-02-10 2012-10-11 Christian Gerdes Immunotherapy
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価抗原結合タンパク質
US20120222851A1 (en) * 2011-03-04 2012-09-06 GM Global Technology Operations LLC Hvac system damper
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
CA2828890A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
KR101992502B1 (ko) 2011-05-12 2019-06-24 제넨테크, 인크. 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
SI2710035T1 (sl) 2011-05-16 2017-07-31 F. Hoffmann-La Roche Ag Agonisti FGFR1 in tehnike njihove uporabe
EA033677B1 (ru) 2011-05-21 2019-11-15 Macrogenics Inc Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
KR101629073B1 (ko) 2011-06-15 2016-06-09 에프. 호프만-라 로슈 아게 항-인간 에리스로포이에틴 수용체 항체 및 이의 사용 방법
BR112013032217B1 (pt) 2011-06-17 2021-01-19 Novo Nordisk A/S uso de um anticorpo anti-nkg2a
BR112013029746B1 (pt) 2011-06-22 2021-02-02 F. Hoffmann-La Roche Ag método para a produção recombinante de um complexo, complexo, formulação farmacêutica e uso do complexo
TW201306866A (zh) 2011-06-30 2013-02-16 Genentech Inc 抗－ｃ－ｍｅｔ抗體調配物
BR112014003599A2 (pt) 2011-08-17 2018-04-17 Genentech Inc método de inibição da angiogênese tumoral, método de supressão do crescimento tumoral e método de tratamento de tumor
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
HRP20181355T1 (hr) 2011-08-23 2018-10-19 Roche Glycart Ag Bispecifične molekule koje se vežu na antigen
CA2844141A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Anti-mcsp antibodies
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2014533927A (ja) 2011-09-15 2014-12-18 ジェネンテック， インコーポレイテッド 分化を促進する方法
CN103930111A (zh) 2011-09-19 2014-07-16 霍夫曼-拉罗奇有限公司 包含c-met拮抗剂和b-raf拮抗剂的组合治疗
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
CA2849011A1 (en) 2011-10-05 2013-04-11 Genentech, Inc. Methods of treating liver conditions using notch2 antagonists
SI2766393T1 (sl) 2011-10-14 2018-10-30 F. Hoffmann-La Roche Ag Protitelesa Anti-HtrA1 in postopki uporabe
RU2014119426A (ru) 2011-10-15 2015-11-20 Дженентек, Инк. Способы применения антагонистов scd1
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
US20140302021A1 (en) 2011-10-25 2014-10-09 Onclave Therapeutics Limited Antibody formulations and methods
CN104039340B (zh) 2011-10-28 2017-04-05 霍夫曼-拉罗奇有限公司 治疗黑素瘤的方法及治疗剂组合
CA2855864A1 (en) * 2011-11-17 2013-05-23 Gundram Jung Bi-specific antibodies for treating b-cell mediated autoimmune diseases or auto-reactive b-cells
AR088920A1 (es) 2011-11-21 2014-07-16 Genentech Inc Purificacion de anticuerpos anti-c-met
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
RU2685867C2 (ru) 2011-12-15 2019-04-23 Алтернатив Инновейтив Текнолоджиз Ллц Гибридные белки и белковые конъюгаты на основе белка теплового шока-70 (БТШ70) и способы их применения (варианты)
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
PL2794635T3 (pl) 2011-12-22 2019-02-28 F.Hoffmann-La Roche Ag Membranowa chromatografia jonowymienna
KR102080356B1 (ko) 2011-12-22 2020-02-24 에프. 호프만-라 로슈 아게 발현 벡터 구성, 신규한 생산 세포 생성 방법 및 폴리펩티드의 재조합 생산을 위한 그의 용도
CN113881702B (zh) 2011-12-22 2025-05-30 弗·哈夫曼-拉罗切有限公司 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
RU2625033C2 (ru) 2011-12-22 2017-07-11 Ф. Хоффманн-Ля Рош Аг Система индикации на основе полноразмерного антитела для эукариотических клеток и ее применение
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
HK1201199A1 (en) 2012-01-18 2015-08-28 霍夫曼-拉罗奇有限公司 Methods of using fgf19 modulators
EA028202B1 (ru) 2012-01-18 2017-10-31 Дженентек, Инк. Анти-lrp5 антитела и способы их применения
AU2012366290A1 (en) * 2012-01-19 2014-08-07 Therapeutic Proteins International, LLC Stabilization of the anti-CD20 antibody Rituximab
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
US20130209473A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
TR201808458T4 (tr) 2012-02-15 2018-07-23 Hoffmann La Roche FC-reseptör bazlı afinite kromatografisi.
SG10201912877SA (en) 2012-03-27 2020-02-27 Genentech Inc Improved harvest operations for recombinant proteins
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243861A1 (en) 2012-04-05 2014-10-23 Ac Immune S.A. Humanized Tau antibody
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
RU2625771C2 (ru) 2012-05-23 2017-07-18 Дженентек, Инк. Способ отбора терапевтических средств
RU2015101113A (ru) 2012-06-15 2016-08-10 Дженентек, Инк. Антитела против pcsk9, составы, дозы и способы применения
WO2014006123A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-biotin antibodies and methods of use
JP6148729B2 (ja) 2012-07-04 2017-06-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 共有結合している抗原−抗体結合体
RU2017128512A (ru) 2012-07-04 2019-02-15 Ф. Хоффманн-Ля Рош Аг Антитела к теофиллину и способы их применения
AU2013285081B2 (en) 2012-07-04 2017-01-12 Rhizen Pharmaceuticals Sa Selective PI3K delta inhibitors
JP6309518B2 (ja) 2012-07-05 2018-04-11 ジェネンテック， インコーポレイテッド 発現及び分泌システム
IN2014DN10510A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-07-09 2015-08-21 Genentech Inc
WO2014011519A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
ES2661572T3 (es) 2012-07-09 2018-04-02 Genentech, Inc. Inmunoconjugados que comprenden anticuerpos anti-CD79b
HK1207973A1 (en) 2012-07-09 2016-02-19 基因泰克公司 Immunoconjugates comprising anti-cd22 antibodies
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
MX2015000681A (es) 2012-08-02 2015-04-10 Hoffmann La Roche Metodo para producir receptores de fc (fcr) solubles como fusion de fc con region de fc de inmunoglobulina inerte y uso de las mismas.
JP6290209B2 (ja) 2012-08-07 2018-03-07 ロシュ グリクアート アーゲー 低下した及び増加したエフェクター機能を有するように操作された２つの抗体を含む組成物。
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP2888238A4 (en) 2012-08-21 2016-01-27 Academia Sinica BENZOCYCLOOCTYN COMPOUNDS AND USES THEREOF
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
WO2014071125A1 (en) 2012-11-02 2014-05-08 Tg Therapeutics, Inc. Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
MA38165A1 (fr) 2012-11-08 2018-07-31 Hoffmann La Roche Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
MA38176A1 (fr) 2012-11-13 2017-06-30 Genentech Inc Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
KR102168562B1 (ko) 2012-11-19 2020-10-22 발리오팜 아게 Cd20 및 cd95에 결합하는 재조합 이중특이성 항체
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US9393327B2 (en) 2012-12-19 2016-07-19 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
CN104884474A (zh) 2012-12-21 2015-09-02 弗·哈夫曼-拉罗切有限公司 包含i类mhc的二硫键连接多价多功能蛋白质
EP3939614A1 (en) 2013-01-18 2022-01-19 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
MX2015010791A (es) 2013-02-22 2015-11-26 Hoffmann La Roche Metodos para tratar el cancer y prevenir la resistencia a farmacos.
RU2015140921A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Антитела к mcsp
HK1213180A1 (zh) 2013-03-06 2016-06-30 豪夫迈‧罗氏有限公司 治疗和预防癌症药物抗性的方法
AU2014249107C1 (en) * 2013-03-12 2018-07-19 Molecular Templates, Inc. CD20-binding immunotoxins for inducing cellular internalization and methods using same
RU2019120404A (ru) 2013-03-13 2019-08-06 Дженентек, Инк. Составы антител
AU2014239903A1 (en) 2013-03-14 2015-09-17 Genentech, Inc. Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EA201591750A1 (ru) 2013-03-14 2016-05-31 Дженентек, Инк. Антитела против b7-h4 и иммуноконъюгаты
RU2015139054A (ru) 2013-03-14 2017-04-19 Дженентек, Инк. Способы лечения рака и профилактики лекарственной резистентности рака
SG10201809452RA (en) * 2013-03-15 2018-11-29 Genentech Inc Cell culture compositions with antioxidants and methods for polypeptide production
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2761260T3 (es) 2013-03-15 2020-05-19 Hoffmann La Roche Biomarcadores y procedimientos de tratamiento de afecciones relacionadas con PD-1 y PD-L1
EP2970422B1 (en) 2013-03-15 2018-04-18 F.Hoffmann-La Roche Ag Il-22 polypeptides and il-22 fc fusion proteins and methods of use
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
KR20150131177A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. 항-CRTh2 항체 및 그의 용도
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
PE20151750A1 (es) 2013-03-15 2015-12-07 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
TWI653243B (zh) 2013-04-29 2019-03-11 赫孚孟拉羅股份公司 遏止ＦｃＲｎ結合之抗ＩＧＦ－１Ｒ抗體及其治療血管性眼疾之用途
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
EP2999716A2 (en) 2013-05-20 2016-03-30 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
KR20160015227A (ko) 2013-05-31 2016-02-12 제넨테크, 인크. 항-세포벽 테이코산 항체 및 접합체
BR112015029754A2 (pt) 2013-05-31 2017-09-26 Genentech Inc anticorpos anti-teicoico da parede e conjugados
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
US10640574B2 (en) 2013-07-18 2020-05-05 Taurus Biosciences, Llc Humanized antibodies with ultralong complementary determining regions
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
KR20250099279A (ko) 2013-08-01 2025-07-01 파이브 프라임 테라퓨틱스, 인크. 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체
WO2015023596A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
CA2922889A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
CN103524621B (zh) * 2013-09-27 2015-04-01 北京济福霖生物技术有限公司 一种抗人cd20嵌合单克隆抗体
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
RU2016117978A (ru) 2013-10-11 2017-11-17 Дженентек, Инк. Ингибиторы nsp4 и способы их применения
JP6502931B2 (ja) 2013-10-11 2019-04-17 アメリカ合衆国 Ｔｅｍ８抗体およびその使用
WO2015052230A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
WO2015058132A2 (en) 2013-10-18 2015-04-23 Genentech, Inc. Anti-rspo antibodies and methods of use
MX2016005159A (es) 2013-10-23 2016-07-05 Genentech Inc Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN111499743B (zh) 2013-11-21 2024-01-12 豪夫迈·罗氏有限公司 抗-α-突触核蛋白抗体及使用方法
PT3079719T (pt) 2013-12-09 2019-12-05 Allakos Inc Anticorpos anti-siglec-8 e métodos de utilização dos mesmos
EA201691214A1 (ru) 2013-12-13 2016-12-30 Дженентек, Инк. Антитела к cd33 и иммуноконъюгаты
JP6449295B2 (ja) 2013-12-17 2019-01-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法
EP3680254A1 (en) 2013-12-17 2020-07-15 F. Hoffmann-La Roche AG Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
EP3083690A1 (en) 2013-12-17 2016-10-26 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
BR112016013562A2 (pt) 2013-12-20 2017-10-03 Hoffmann La Roche Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
MX373097B (es) 2014-01-03 2020-04-27 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de barrera hematoencefálica, complejos de los mismos y su uso como transportadores a través de la barrera hematoencefálica.
JP6602304B2 (ja) 2014-01-03 2019-11-06 エフ．ホフマン−ラ ロシュ アーゲー 共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
CA2930046A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked polypeptide toxin-antibody conjugates
CN111057147B (zh) 2014-01-06 2023-11-10 豪夫迈·罗氏有限公司 单价血脑屏障穿梭模块
CN105899534B (zh) 2014-01-15 2020-01-07 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015112909A1 (en) 2014-01-24 2015-07-30 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
JP6655017B2 (ja) 2014-01-27 2020-02-26 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. Ｍｈｃクラスｉエピトープ送達ポリペプチド
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
CN112826930A (zh) 2014-02-08 2021-05-25 豪夫迈·罗氏有限公司 治疗阿尔茨海默氏病的方法
MX380252B (es) 2014-02-08 2025-03-12 Genentech Inc Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
LT3105253T (lt) 2014-02-12 2018-09-10 F. Hoffmann-La Roche Ag Antikūnai prieš jagged1 ir jų naudojimo būdai
EP3107574A2 (en) 2014-02-21 2016-12-28 F. Hoffmann-La Roche AG Anti-il-13/il-17 bispecific antibodies and uses thereof
TWI558399B (zh) 2014-02-26 2016-11-21 美國禮來大藥廠 癌症之組合療法
US10183996B2 (en) 2014-02-28 2019-01-22 Allakos Inc. Methods and compositions for treating Siglec-8 associated diseases
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
WO2015139046A1 (en) 2014-03-14 2015-09-17 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
EP3119490B1 (en) 2014-03-21 2021-09-08 F. Hoffmann-La Roche AG In vitro prediction of in vivo half-life of antibodies
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
BR112016022345A2 (pt) 2014-03-31 2017-10-10 Genentech Inc terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
BR112016022658A2 (pt) 2014-03-31 2017-10-17 Genentech Inc anticorpos anti-ox40 e métodos de uso
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
BR112016027222A2 (pt) 2014-05-22 2018-01-30 Genentech Inc anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
AU2015267047A1 (en) 2014-05-27 2017-01-05 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170010003A (ko) 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
BR112016027674A2 (pt) 2014-05-27 2017-08-15 Rhizen Pharmaceuticals Sa Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas
AU2015267044A1 (en) 2014-05-28 2016-12-15 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
EP3137488B1 (en) 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
EP3155015A1 (en) 2014-06-11 2017-04-19 F. Hoffmann-La Roche AG Anti-lgr5 antibodies and uses thereof
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
JP6654581B2 (ja) 2014-06-26 2020-02-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｂｒｄｕ抗体および使用方法
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
MX2017000363A (es) 2014-07-11 2017-04-27 Genentech Inc Inhibicion de la via de notch.
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
AU2015308818B2 (en) 2014-08-28 2021-02-25 Bioatla Llc Conditionally active chimeric antigen receptors for modified T-cells
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
US20170246272A1 (en) 2014-09-05 2017-08-31 Opexa Therapeutics, Inc. Compositions and methods for treating b cell mediated autoimmune disorders
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
JP6886398B2 (ja) 2014-09-12 2021-06-16 ジェネンテック， インコーポレイテッド Ａｎｔｉ−ｃｌｌ−１抗体及び免疫複合体
DK3191135T3 (da) 2014-09-12 2020-10-12 Genentech Inc Anti-HER2-antistoffer og immunokonjugater
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
HK1243629A1 (zh) 2014-09-17 2018-07-20 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
WO2016049214A1 (en) 2014-09-23 2016-03-31 Genentech, Inc. METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
EP3207057A2 (en) 2014-10-16 2017-08-23 F. Hoffmann-La Roche AG Anti-alpha-synuclein antibodies and methods of use
EP3223865A4 (en) 2014-10-31 2018-10-03 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
US20160160290A1 (en) 2014-11-03 2016-06-09 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
SG11201703448QA (en) 2014-11-03 2017-05-30 Genentech Inc Assays for detecting t cell immune subsets and methods of use thereof
KR102709593B1 (ko) 2014-11-05 2024-09-26 제넨테크, 인크. 박테리아 내 2쇄 단백질을 생산하는 방법
EP3753948A1 (en) 2014-11-05 2020-12-23 Genentech, Inc. Methods of producing two chain proteins in bacteria
BR112017008666A2 (pt) 2014-11-05 2018-01-30 Genentech, Inc. anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
KR20170076697A (ko) 2014-11-06 2017-07-04 에프. 호프만-라 로슈 아게 개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체
RU2714116C2 (ru) 2014-11-06 2020-02-11 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМ СВЯЗЫВАНИЕМ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3552488A1 (en) 2014-11-10 2019-10-16 F. Hoffmann-La Roche AG Animal model for nephropathy and agents for treating the same
WO2016077381A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US10160795B2 (en) 2014-11-14 2018-12-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to Ebola virus glycoprotein and their use
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
US11008403B2 (en) 2014-11-19 2021-05-18 Genentech, Inc. Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
JP6859259B2 (ja) 2014-11-19 2021-04-14 ジェネンテック， インコーポレイテッド ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
EP4141032B1 (en) 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
HK1244230A1 (zh) 2014-12-03 2018-08-03 F. Hoffmann-La Roche Ag 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
RU2731055C2 (ru) 2014-12-03 2020-08-28 Дженентек, Инк. Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
KR20170086549A (ko) 2014-12-05 2017-07-26 제넨테크, 인크. 항-CD79b 항체 및 이용 방법
CN107207591A (zh) 2014-12-10 2017-09-26 豪夫迈·罗氏有限公司 血脑屏障受体抗体及使用方法
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3945096A1 (en) 2014-12-19 2022-02-02 Regenesance B.V. Antibodies that bind human c6 and uses thereof
RU2746356C2 (ru) 2014-12-19 2021-04-12 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
MX2017009254A (es) 2015-01-16 2017-10-12 Juno Therapeutics Inc Anticuerpos y receptores de antigeno quimerico especificos para ror1.
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CN107428823B (zh) 2015-01-22 2021-10-26 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
WO2016118191A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
EP3250605A1 (en) * 2015-01-26 2017-12-06 Cellectis Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy
EP3253784B1 (en) 2015-02-04 2020-05-06 Genentech, Inc. Mutant smoothened and methods of using the same
CA2974547A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
CA2972151C (en) 2015-02-05 2022-10-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
KR20170140180A (ko) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
KR20170127011A (ko) 2015-03-16 2017-11-20 제넨테크, 인크. Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
WO2016154003A1 (en) 2015-03-20 2016-09-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to gp120 and their use
EP3274370B1 (en) 2015-03-23 2019-11-20 Bayer Pharma Aktiengesellschaft Anti-ceacam6 antibodies and uses thereof
KR20170129902A (ko) 2015-03-23 2017-11-27 조운스 테라퓨틱스, 인크. Icos에 대한 항체
EP3274368A1 (en) 2015-03-25 2018-01-31 THE UNITED STATES OF AMERICA, represented by the S Bispecific multivalent fusion proteins
AU2016243026B2 (en) 2015-04-03 2022-03-31 Eureka Therapeutics, Inc. Constructs targeting AFP peptide/MHC complexes and uses thereof
KR20180002653A (ko) 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
SI3286315T1 (sl) 2015-04-24 2021-09-30 F. Hoffmann-La Roche Ag Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide
HK1252158A1 (zh) 2015-05-01 2019-05-17 Genentech, Inc. 掩蔽抗cd3抗体和使用方法
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
EP3936524A3 (en) 2015-05-11 2022-06-15 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
PT3294770T (pt) 2015-05-12 2020-12-04 Hoffmann La Roche Métodos terapêuticos e diagnósticos para o cancro
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
WO2016196343A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Humanized anti-ebola virus glycoprotein antibodies and methods of use
HK1248773A1 (zh) 2015-05-29 2018-10-19 豪夫迈‧罗氏有限公司 用於癌症的治疗和诊断方法
KR20180013881A (ko) 2015-05-29 2018-02-07 제넨테크, 인크. 암에서의 pd-l1 프로모터 메틸화
EP3660035A1 (en) 2015-05-30 2020-06-03 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
WO2016196679A1 (en) 2015-06-02 2016-12-08 Genentech, Inc. Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
MX392257B (es) 2015-06-05 2025-03-24 Genentech Inc Anticuerpos anti-tau y metodos de uso
JP2018518483A (ja) 2015-06-08 2018-07-12 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
CN107810011A (zh) 2015-06-08 2018-03-16 豪夫迈·罗氏有限公司 使用抗ox40抗体治疗癌症的方法
TW201709934A (zh) 2015-06-15 2017-03-16 建南德克公司 抗體及免疫結合物
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
FI3310814T3 (fi) 2015-06-16 2023-09-21 Hoffmann La Roche HUMANISOITUJA JA AFFINITEETTIKYPSIÄ FcRH5-VASTA-AINEITA JA KÄYTTÖMENETELMIÄ
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
JP2018524312A (ja) 2015-06-17 2018-08-30 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体及び使用方法
CN116327953A (zh) 2015-06-17 2023-06-27 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
JP6846362B2 (ja) 2015-06-17 2021-03-24 アラコス インコーポレイテッド 線維性疾患を処置するための方法および組成物
US9862763B2 (en) 2015-06-24 2018-01-09 Hoffmann-La Roche Inc. Humanized anti-tau(pS422) antibodies and methods of use
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
WO2016207091A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
CN108473573A (zh) 2015-06-29 2018-08-31 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于器官移植中
EP3514174B1 (en) 2015-06-29 2021-03-31 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3341415B1 (en) 2015-08-28 2021-03-24 H. Hoffnabb-La Roche Ag Anti-hypusine antibodies and uses thereof
CN113372443A (zh) 2015-09-18 2021-09-10 中外制药株式会社 Il-8-结合抗体及其应用
WO2017050729A1 (en) 2015-09-22 2017-03-30 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
EP3353203A2 (en) * 2015-09-23 2018-08-01 H. Hoffnabb-La Roche Ag Optimized variants of anti-vegf antibodies
RU2757135C2 (ru) 2015-09-24 2021-10-11 АБВИТРО ЭлЭлСи Композиции антител к вич и способы их применения
NZ758624A (en) 2015-09-25 2025-06-27 Genentech Inc Anti-tigit antibodies and methods of use
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PT3356404T (pt) 2015-10-02 2021-10-14 Hoffmann La Roche Anticorpos anti-pd1 e métodos de utilização
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
CN114057884A (zh) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
AU2016329120B2 (en) 2015-10-02 2023-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory TNF receptor
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
JP6622392B2 (ja) 2015-10-02 2019-12-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１とｔｉｍ３に特異的な二重特異性抗体
LT3359572T (lt) 2015-10-06 2025-02-10 F. Hoffmann-La Roche Ag Išsėtinės sklerozės gydymo būdas
AU2016335750B2 (en) 2015-10-07 2023-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
US20170247467A1 (en) 2015-10-07 2017-08-31 Hoffmann-La Roche Inc. Bispecific antibodies with tetravalency for a costimulatory tnf receptor
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
HK1258249A1 (zh) 2015-10-22 2019-11-08 震动疗法股份有限公司 用於测定icos表达的基因标志
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
EP4015533A1 (en) 2015-10-29 2022-06-22 F. Hoffmann-La Roche AG Anti-variant fc-region antibodies and methods of use
CN108290957B (zh) 2015-10-30 2022-06-17 豪夫迈·罗氏有限公司 抗-HtrA1抗体及其使用方法
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
AU2016349392B2 (en) 2015-11-03 2023-07-13 The Trustees Of Columbia University In The City Of New York Neutralizing antibodies to HIV-1 gp41 and their use
EP3371217B1 (en) 2015-11-08 2025-06-11 F. Hoffmann-La Roche AG Methods of screening for multispecific antibodies
KR102777244B1 (ko) 2015-11-23 2025-03-11 파이브 프라임 테라퓨틱스, 인크. 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
JP7325186B2 (ja) 2015-12-09 2023-08-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体
MY189425A (en) 2015-12-18 2022-02-10 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JP6088703B1 (ja) 2015-12-18 2017-03-01 中外製薬株式会社 抗ｃ５抗体および使用方法
CN108472379B (zh) 2015-12-30 2022-06-21 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
CN108368179B (zh) 2016-01-08 2022-08-23 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
US20190016791A1 (en) 2016-01-20 2019-01-17 Genentech, Inc. High dose treatments for alzheimer's disease
EP3411396A1 (en) 2016-02-04 2018-12-12 Curis, Inc. Mutant smoothened and methods of using the same
KR102500659B1 (ko) 2016-02-29 2023-02-16 제넨테크, 인크. 암에 대한 치료 및 진단 방법
EP3423491A1 (en) 2016-03-01 2019-01-09 H. Hoffnabb-La Roche Ag Obinutuzumab variants having altered cell death induction
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
US11767362B1 (en) 2016-03-15 2023-09-26 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
SG11201808562SA (en) 2016-03-29 2018-10-30 Geltor Inc Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
KR101796277B1 (ko) * 2016-04-12 2017-11-13 앱클론(주) 안정성이 개선된 ｈｅｒ２에 특이적으로 결합하는 항체
EP3865511A1 (en) 2016-04-14 2021-08-18 F. Hoffmann-La Roche AG Anti-rspo3 antibodies and methods of use
WO2017180842A1 (en) 2016-04-15 2017-10-19 Bioatla, Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
IL262365B2 (en) 2016-04-15 2024-11-01 Alpine Immune Sciences Inc Immunomodulatory proteins ICOS ligand variants and uses thereof
JP7503887B2 (ja) 2016-04-15 2024-06-21 ジェネンテック， インコーポレイテッド がんを監視及び治療するための方法
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
AU2017248766A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
MA56474A (fr) 2016-05-02 2022-05-11 Hoffmann La Roche Contorsbody - liant de cible à chaîne unique
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
KR20240148936A (ko) 2016-05-13 2024-10-11 바이오아트라, 인코퍼레이티드 항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
BR112018074238A2 (pt) 2016-05-27 2019-04-16 Tg Therapeutics, Inc. combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
AU2018276419A1 (en) 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN109476648B (zh) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
EP3472200A4 (en) 2016-06-17 2020-04-01 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE THEREOF
JP7133477B2 (ja) 2016-06-24 2022-09-08 ジェネンテック， インコーポレイテッド 抗ポリユビキチン多重特異性抗体
WO2018007314A1 (en) 2016-07-04 2018-01-11 F. Hoffmann-La Roche Ag Novel antibody format
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
CA3031734A1 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
WO2018022438A1 (en) 2016-07-29 2018-02-01 Eli Lilly And Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
AU2017321973B2 (en) 2016-09-02 2024-09-05 Dana-Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
EP3510046A4 (en) 2016-09-07 2020-05-06 The Regents of the University of California ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
EP3509634A1 (en) 2016-09-09 2019-07-17 TG Therapeutics Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP6976315B2 (ja) 2016-09-19 2021-12-08 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 補体因子に基づくアフィニティークロマトグラフィー
EP4268845A3 (en) 2016-09-23 2024-02-28 F. Hoffmann-La Roche AG Uses of il-13 antagonists for treating atopic dermatitis
MA46354A (fr) 2016-10-03 2019-08-07 Juno Therapeutics Inc Molécules se liant spécifiquement au vph
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
KR102804118B1 (ko) 2016-10-06 2025-05-09 제넨테크, 인크. 암에 대한 치료 및 진단 방법
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
PT3535298T (pt) 2016-11-02 2021-11-25 Jounce Therapeutics Inc Anticorpos para pd-1 e seu uso
US20190284261A1 (en) * 2016-11-07 2019-09-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs for use against lyme disease
JP2020503260A (ja) 2016-11-15 2020-01-30 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
ES2866348T3 (es) 2016-11-16 2021-10-19 Lilly Co Eli Terapia de combinación para el cáncer con mutación o mutaciones de omisión del exón 14 o fenotipo de omisión del exón 14
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
CA3036983A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
EP3608333A1 (en) 2016-12-07 2020-02-12 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
CN118165104A (zh) 2016-12-07 2024-06-11 基因泰克公司 抗tau抗体和使用方法
EP3551655A2 (en) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of their use
CN110366562A (zh) 2016-12-12 2019-10-22 豪夫迈·罗氏有限公司 使用抗pd-l1抗体和抗雄激素治疗癌症的方法
MX2019006954A (es) 2016-12-20 2019-08-01 Hoffmann La Roche Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
CN110461873B (zh) 2017-01-03 2023-05-12 豪夫迈·罗氏有限公司 包含抗4-1bb克隆20h4.9的双特异性抗原结合分子
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2018132597A1 (en) 2017-01-12 2018-07-19 Eureka Therapeutics, Inc. Constructs targeting histone h3 peptide/mhc complexes and uses thereof
ES2971981T3 (es) 2017-01-25 2024-06-10 Molecular Templates Inc Moléculas de reconocimiento de células que comprenden efectores de la subunidad A de la toxina Shiga desinmunizados y epítopos de células T CD8+
KR102365871B1 (ko) 2017-01-31 2022-02-21 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
US11021535B2 (en) 2017-02-10 2021-06-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
CN110494453B (zh) 2017-02-10 2023-05-26 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
JP7256127B2 (ja) 2017-03-01 2023-04-11 ジェネンテック， インコーポレイテッド がんのための診断及び治療方法
LT3596116T (lt) 2017-03-16 2023-11-10 Alpine Immune Sciences, Inc. Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
EP3596114A2 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
UA129242C2 (uk) 2017-03-22 2025-02-26 Дженентек, Інк. Оптимізована композиція антитіла для лікування захворювань очей
MA49270A (fr) 2017-03-27 2020-02-05 Hoffmann La Roche Récepteurs de liaison à l'antigène améliorés
TWI848907B (zh) 2017-03-28 2024-07-21 美商建南德克公司 治療神經退化性疾病之方法
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
EP3606963B1 (en) 2017-04-03 2023-08-30 F. Hoffmann-La Roche AG Antibodies binding to steap-1
MA49039A (fr) 2017-04-04 2020-02-12 Hoffmann La Roche Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
KR102346336B1 (ko) 2017-04-05 2022-01-04 에프. 호프만-라 로슈 아게 Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
ES2926859T3 (es) 2017-04-05 2022-10-31 Hoffmann La Roche Anticuerpos anti-LAG3
WO2018191660A1 (en) 2017-04-14 2018-10-18 Genentech, Inc. Diagnostic and therapeutic methods for cancer
PE20200150A1 (es) 2017-04-21 2020-01-17 Genentech Inc Uso de antagonistas de klk5 para el tratamiento de una enfermedad
IL319308A (en) 2017-04-26 2025-04-01 Eureka Therapeutics Inc ׂ A Delaware Corp Structures that specifically recognize glypican 3 and their uses
WO2018201096A1 (en) 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
US11203638B2 (en) 2017-05-05 2021-12-21 Allakos Inc. Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
BR112019023898A2 (pt) 2017-05-16 2020-06-09 Five Prime Therapeutics Inc método para tratamento de câncer gástrico, uso de um anticorpo e composição
CN110831969B (zh) 2017-06-20 2024-06-21 安进公司 使用抑胃肽受体（gipr）结合蛋白与glp-1激动剂的组合治疗或改善代谢障碍的方法
US11674962B2 (en) 2017-07-21 2023-06-13 Genentech, Inc. Therapeutic and diagnostic methods for cancer
JP2020528061A (ja) 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
JP7122370B2 (ja) 2017-07-26 2022-08-19 フォーティ セブン， インコーポレイテッド 抗ｓｉｒｐ－アルファ抗体及び関連方法
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
JP7382922B2 (ja) 2017-09-20 2023-11-17 中外製薬株式会社 Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
EA202090641A1 (ru) 2017-09-29 2020-08-07 Чугаи Сейяку Кабусики Кайся Мультиспецифическая антиген-связывающая молекула, обладающая замещающей функциональной активностью кофактора коагулирующего фактора крови viii, и фармацевтическая композиция, содержащая указанную молекулу в качестве активного ингредиента
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
CN111801347A (zh) 2017-10-10 2020-10-20 高山免疫科学股份有限公司 Ctla-4变体免疫调节蛋白和其用途
CN111372950B (zh) 2017-10-12 2024-11-05 免疫苏醒公司 Vegfr-抗体轻链融合蛋白
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
BR112020007586A2 (pt) 2017-10-17 2020-09-24 Rhizen Pharmaceuticals Sa moduladores de canal de crac para tratar câncer esofágico
SG11202003078VA (en) 2017-10-18 2020-05-28 Alpine Immune Sciences Inc Variant icos ligand immunomodulatory proteins and related compositions and methods
CA3078157A1 (en) 2017-10-20 2019-04-25 F.Hoffmann-La Roche Ag Method for generating multispecific antibodies from monospecific antibodies
WO2019082124A1 (en) 2017-10-26 2019-05-02 Rhizen Pharmaceuticals Sa COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA
SG11202003437PA (en) 2017-10-30 2020-05-28 Rhizen Pharmaceuticals Sa Calcium release-activated calcium channel modulators for treating hematological and solid cancers
CA3078676A1 (en) 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
AU2018359967A1 (en) 2017-11-06 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHODS OF USE
EP3717516A1 (en) 2017-12-01 2020-10-07 Pfizer Inc Anti-cxcr5 antibodies and compositions and uses thereof
JP2021505571A (ja) 2017-12-06 2021-02-18 ルヒゼン ファーマスティカルズ エスエー 末梢ｔ細胞リンパ腫および皮膚ｔ細胞リンパ腫を治療するための組成物および方法
TW201934578A (zh) 2017-12-14 2019-09-01 瑞士商赫孚孟拉羅股份公司 治療方法
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
PE20201149A1 (es) 2017-12-21 2020-10-26 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1
EA202091540A1 (ru) 2017-12-22 2021-03-22 Джаунс Терапьютикс, Инк. Антитела к lilrb2
TW201929907A (zh) 2017-12-22 2019-08-01 美商建南德克公司 Pilra結合劑用於治療疾病之用途
WO2019129221A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
AU2018396964C1 (en) 2017-12-28 2024-10-03 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against PD-L1
WO2019129677A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
WO2019136029A1 (en) 2018-01-02 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
US12297253B2 (en) 2018-01-03 2025-05-13 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN118955720A (zh) 2018-01-04 2024-11-15 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
MX2020006956A (es) 2018-01-05 2020-11-06 Ac Immune Sa Moleculas de union a tdp-43 mal plegadas.
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
KR20250114571A (ko) 2018-01-15 2025-07-29 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
US20200339686A1 (en) 2018-01-16 2020-10-29 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
JP7349995B2 (ja) 2018-01-26 2023-09-25 ジェネンテック， インコーポレイテッド ＩＬ－２２ Ｆｃ融合タンパク質及び使用方法
TWI835773B (zh) 2018-01-26 2024-03-21 美商建南德克公司 組合物及使用方法
AU2019214183B2 (en) 2018-02-01 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
US11866498B2 (en) 2018-02-08 2024-01-09 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
MX2020008291A (es) 2018-02-09 2020-09-25 Genentech Inc Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos.
US11591399B2 (en) 2018-02-14 2023-02-28 Abba Therapeutics Ag Anti-human PD-L2 antibodies
EP3755713A1 (en) 2018-02-21 2020-12-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 env and their use
MX2020008502A (es) 2018-02-21 2020-09-25 Genentech Inc Dosis para el tratamiento con proteinas de fusion il-22 fc.
US20200399376A1 (en) 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
PL3765489T3 (pl) 2018-03-13 2025-02-10 F. Hoffmann-La Roche Ag Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
RU2020128013A (ru) 2018-03-14 2022-04-15 Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. Антитела против клаудина 18.2
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
SG11202009010RA (en) 2018-03-15 2020-10-29 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
JP2021519073A (ja) 2018-03-29 2021-08-10 ジェネンテック， インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
TW202003567A (zh) 2018-03-30 2020-01-16 大陸商南京傳奇生物科技有限公司 針對lag-3之單一結構域抗體及其用途
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
MX2020010460A (es) 2018-04-05 2021-01-29 Juno Therapeutics Inc Receptores de células t, y células diseñadas que expresan los mismos.
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
CN110464842B (zh) 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途
EP3794024B1 (en) 2018-05-14 2023-05-10 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CA3100018A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
WO2019228514A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
EP3805400A4 (en) 2018-06-04 2022-06-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule showing changed half-life in cytoplasm
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
CN112469440B (zh) 2018-06-18 2024-09-06 优瑞科生物技术公司 靶向前列腺特异性膜抗原(psma)的构建体和其用途
CN112585166A (zh) 2018-06-23 2021-03-30 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
CN112424228B (zh) 2018-07-04 2024-08-09 豪夫迈·罗氏有限公司 新型双特异性激动性4-1bb抗原结合分子
CN112384219A (zh) 2018-07-09 2021-02-19 千禧制药公司 Sumo-激活酶抑制剂和抗cd20抗体的施用
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CA3104147A1 (en) 2018-07-18 2020-01-23 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020018879A1 (en) 2018-07-20 2020-01-23 Surface Oncology, Inc. Anti-cd112r compositions and methods
TWI704157B (zh) 2018-08-01 2020-09-11 日商中外製藥股份有限公司 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法
EP3831854A4 (en) 2018-08-03 2022-05-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING TWO ANTIGEN-BINDING DOMAINS LINKED TO EACH OTHER
CA3051549A1 (en) 2018-08-09 2020-02-09 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
PE20210343A1 (es) 2018-08-10 2021-02-23 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso
EP3836966A4 (en) 2018-08-17 2022-06-08 Ab Studio Inc. CATALYTIC ANTIBODIES AND THEIR METHODS OF USE
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CA3111458A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
CA3111401A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
KR20210089146A (ko) 2018-09-19 2021-07-15 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
AU2019342133B8 (en) 2018-09-21 2025-08-07 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
SG11202102777PA (en) 2018-09-27 2021-04-29 Xilio Development Inc Masked cytokine polypeptides
JP7221379B2 (ja) 2018-10-01 2023-02-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｆａｐクローン２１２を含む二重特異性抗原結合分子
EP3861025A1 (en) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules with trivalent binding to cd40
BR112021005204A2 (pt) 2018-10-05 2021-06-08 Five Prime Therapeutics, Inc. formulações farmacêuticas e método para tratar um tumor sólido
EP3868784A4 (en) 2018-10-15 2022-07-27 Industry-Academic Cooperation Foundation, Yonsei University ANTIBODIES WITH INCREASED PRODUCTIVITY AND METHODS FOR THEIR PRODUCTION
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
WO2020081767A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
US20210395390A1 (en) 2018-10-31 2021-12-23 Bayer Aktiengesellschaft Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
CN113260626B (zh) 2018-11-05 2024-09-13 豪夫迈·罗氏有限公司 在原核宿主细胞中产生双链蛋白质的方法
WO2020102555A1 (en) 2018-11-16 2020-05-22 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
EP3904382A4 (en) 2018-11-27 2022-07-13 Innovent Biologics (Suzhou) Co., Ltd. ANTI-IL-23P19 ANTIBODIES AND ITS USES
MY209069A (en) 2018-11-27 2025-06-18 Staidson Beijing Biopharmaceuticals Co Ltd Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
US20220372106A1 (en) 2018-11-30 2022-11-24 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
WO2020117952A2 (en) 2018-12-05 2020-06-11 Genentech, Inc. Diagnostic methods and compositions for cancer immunotherapy
MX2021006573A (es) 2018-12-06 2021-07-15 Genentech Inc Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
WO2020132214A2 (en) 2018-12-20 2020-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
AR117453A1 (es) 2018-12-20 2021-08-04 Genentech Inc Fc de anticuerpos modificados y métodos para utilizarlas
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
JP2022514950A (ja) 2018-12-21 2022-02-16 ２３アンドミー・インコーポレイテッド 抗ｉｌ－３６抗体およびその使用方法
CN119708249A (zh) 2018-12-21 2025-03-28 豪夫迈·罗氏有限公司 与VEGF和IL-1β结合的抗体及其使用方法
WO2020132231A1 (en) 2018-12-21 2020-06-25 Genentech, Inc. Methods of producing polypeptides using a cell line resistant to apoptosis
CN118271445A (zh) 2018-12-21 2024-07-02 豪夫迈·罗氏有限公司 与cd3结合的抗体
EP3902833A2 (en) 2018-12-26 2021-11-03 City of Hope Activatable masked anti-ctla4 binding proteins
WO2020141145A1 (en) 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Anti-rabbit cd19 antibodies and methods of use
CN115120716A (zh) 2019-01-14 2022-09-30 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
CA3126359A1 (en) 2019-01-22 2020-07-30 Genentech, Inc. Immunoglobulin a antibodies and methods of production and use
US12263234B2 (en) 2019-01-23 2025-04-01 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-PD-L1 diabodies and the use thereof
JP7658905B2 (ja) 2019-01-23 2025-04-08 ジェネンテック， インコーポレイテッド 真核宿主細胞において多量体タンパク質を産生する方法
WO2020153467A1 (ja) 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
MA54863A (fr) 2019-01-29 2021-12-08 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1)
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
KR20210133237A (ko) 2019-02-27 2021-11-05 제넨테크, 인크. 항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
MX2021010254A (es) 2019-02-27 2021-09-21 Angiex Inc Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
BR112021017144A2 (pt) 2019-03-08 2021-11-09 Genentech Inc Ensaio para detectar uma proteína associada à membrana, métodos para quantificar a concentração de proteína circulante, para determinar se um paciente com linfoma de células b tem probabilidade de exibir uma resposta a uma terapia anti-cd20, para determinar a afinidade de um anticorpo anti-cd20, para determinar a ativação de células t e método de tratamento de um tumor
UA128654C2 (uk) 2019-03-14 2024-09-18 Дженентек, Інк. Лікування раку біспецифічними антитілами до her2xcd3 у комбінації з моноклональним антитілом до her2
TWI856084B (zh) 2019-04-01 2024-09-21 美商建南德克公司 用於穩定含有蛋白質之配方之組合物及方法
CN113993885B (zh) 2019-04-12 2025-04-25 格尔托公司 重组弹性蛋白及其生产
MX2021012607A (es) 2019-04-17 2022-03-11 Alpine Immune Sciences Inc Metodos y usos de proteinas de fusion de ligando icos (icosl) variante.
CA3133909A1 (en) 2019-04-18 2020-10-22 Elpida TSIKA Novel molecules for therapy and diagnosis
TWI888376B (zh) 2019-04-19 2025-07-01 日商中外製藥股份有限公司 辨識抗體改變部位之嵌合受體
KR20220002967A (ko) 2019-04-19 2022-01-07 제넨테크, 인크. 항 mertk 항체 및 이의 사용 방법
EP3962523A2 (en) 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
MX2021013222A (es) 2019-05-03 2022-01-06 Genentech Inc Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
EP3968993A1 (en) 2019-05-14 2022-03-23 F. Hoffmann-La Roche AG Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
CA3137512A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
SG11202112453TA (en) 2019-05-23 2021-12-30 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
AU2020291300A1 (en) 2019-06-10 2022-01-06 Chugai Seiyaku Kabushiki Kaisha Anti-T cell antigen-binding molecule to be used in combination with cytokine inhibitor
US20220380474A1 (en) 2019-07-02 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Monoclonal antibodies that bind egfrviii and their use
KR20220029710A (ko) 2019-07-09 2022-03-08 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 슈도모나스 pcrv를 특이적으로 인식하는 항체 및 이의 용도
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
EP3998083A4 (en) 2019-07-12 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Anti-mutation type fgfr3 antibody and use therefor
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
WO2021018925A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d
WO2021019036A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
EP4003526A2 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Antibodies binding to gprc5d
AU2020319677A1 (en) 2019-07-31 2022-01-06 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
TWI832183B (zh) 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
EP4028054A1 (en) 2019-09-12 2022-07-20 Genentech, Inc. Compositions and methods of treating lupus nephritis
CN114981303B (zh) * 2019-09-13 2024-01-23 安徽俊义医疗管理咨询有限公司 人源化抗Claudin18.2（CLDN18.2）抗体
CR20220156A (es) 2019-09-18 2022-05-23 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
CA3147179A1 (en) 2019-09-20 2021-03-25 Joseph Haw-Ling Lin Dosing for anti-tryptase antibodies
CN114746119A (zh) 2019-09-27 2022-07-12 詹森生物科技公司 抗-ceacam抗体及其用途
CN114555116A (zh) 2019-09-27 2022-05-27 豪夫迈·罗氏有限公司 用于抗tigit和抗pd-l1拮抗剂抗体治疗的给药
JP2023507053A (ja) * 2019-10-12 2023-02-21 バイオ－セラ ソリューションズ リミテッド 抗ｃｄ２０抗体製剤及びｃｄ２０陽性疾患の治療のための抗ｃｄ２０抗体の使用
CN114945386A (zh) 2019-10-18 2022-08-26 基因泰克公司 使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
IL292378A (en) 2019-10-21 2022-06-01 Rhizen Pharmaceuticals Ag Preparations that include a dhodh inhibitor for the treatment of acute myeloid leukemia
CA3155922A1 (en) 2019-11-06 2021-05-14 Huang Huang Diagnostic and therapeutic methods for treatment of hematologic cancers
EP4058593A4 (en) 2019-11-12 2023-11-15 Foundation Medicine, Inc. METHOD FOR DETECTING A FUSION GENE CODING A NEOANTIGEN
KR20220101147A (ko) 2019-11-14 2022-07-19 웨어울프 세라퓨틱스, 인크. 활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법
KR20220110539A (ko) 2019-12-04 2022-08-08 에이씨 이뮨 에스에이 치료 및 진단용 신규 분자
JP7751577B2 (ja) 2019-12-06 2025-10-08 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
IL293430A (en) 2019-12-06 2022-07-01 Juno Therapeutics Inc Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
CN114867494B9 (zh) 2019-12-13 2024-01-12 基因泰克公司 抗ly6g6d抗体及使用方法
US11987632B2 (en) 2019-12-18 2024-05-21 Hoffmann-La Roche Inc. Antibodies binding to HLA-A2/MAGE-A4
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
IL294226B2 (en) 2019-12-27 2025-05-01 Chugai Pharmaceutical Co Ltd Anti-CTLA-4 antibodies and their use
IL321341A (en) 2020-01-06 2025-08-01 Vaccinex Inc Anti-CCR8 antibodies and their uses
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP4096708A1 (en) 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
CA3165319A1 (en) 2020-01-31 2021-08-05 Vincent K. Tuohy Anti-mullerian hormone receptor 2 antibodies and methods of use
CA3167808A1 (en) 2020-02-12 2021-08-19 Chugai Seiyaku Kabushiki Kaisha Anti-cd137 antigen-binding molecule for use in cancer treatment
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
EP4093762A1 (en) 2020-02-20 2022-11-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Epstein-barr virus monoclonal antibodies and uses thereof
EP4110826A4 (en) 2020-02-28 2024-08-14 Shanghai Henlius Biotech, Inc. ANTI-CD137 CONSTRUCTS, MULTI-SPECIFIC ANTIBODY AND ITS USES
JP7715722B2 (ja) 2020-02-28 2025-07-30 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト及びその使用
EP4114445A1 (en) 2020-03-06 2023-01-11 Ona Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
PE20230252A1 (es) 2020-03-13 2023-02-07 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos de estos
IL318520A (en) 2020-03-19 2025-03-01 Genentech Inc Isoform-selective anti-TGF-β antibodies and methods of use
BR112022018847A2 (pt) 2020-03-24 2022-11-22 Genentech Inc Anticorpos, ácido nucleico, célula hospedeira, conjugados, composição farmacêutica, dispositivo de entrega de ação prolongada para entrega ocular, método para tratar um distúrbio e uso do anticorpo
KR20220159426A (ko) 2020-03-26 2022-12-02 제넨테크, 인크. 감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
JP7674383B2 (ja) 2020-03-30 2025-05-09 エフ． ホフマン－ラ ロシュ アーゲー Ｖｅｇｆ及びｐｄｇｆ－ｂに結合する抗体及び使用方法
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
JP2023520515A (ja) 2020-04-03 2023-05-17 ジェネンテック， インコーポレイテッド がんに対する治療方法及び診断方法
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
PE20230078A1 (es) 2020-04-24 2023-01-11 Hoffmann La Roche Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados
TW202206111A (zh) 2020-04-24 2022-02-16 美商建南德克公司 使用抗ｃｄ７９ｂ免疫結合物之方法
WO2021222181A2 (en) 2020-04-27 2021-11-04 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
WO2021222167A1 (en) 2020-04-28 2021-11-04 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
WO2021225892A1 (en) 2020-05-03 2021-11-11 Levena (Suzhou) Biopharma Co., Ltd. Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
CA3178882A1 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins and methods of use thereof
CA3177717A1 (en) 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer
CN113993900B (zh) 2020-05-27 2023-08-04 舒泰神（北京）生物制药股份有限公司 特异性识别神经生长因子的抗体及其用途
CA3178417A1 (en) 2020-05-29 2021-12-02 Yu Chen Anti-cd200r1 antibodies and methods of use thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
TW202210515A (zh) 2020-06-02 2022-03-16 美商當康生物科技有限公司 抗ｃｄ３９之構築體及其用途
BR112022024996A2 (pt) 2020-06-08 2022-12-27 Hoffmann La Roche Anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, agente terapêutico, uso do anticorpo e método para tratar um indivíduo com hepatite b
CN115698719A (zh) 2020-06-12 2023-02-03 基因泰克公司 用于癌症免疫疗法的方法和组合物
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
IL298946A (en) 2020-06-18 2023-02-01 Genentech Inc Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
IL296089A (en) 2020-06-19 2022-11-01 Hoffmann La Roche Antibodies binding to cd3
WO2021255143A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and folr1
CA3180951A1 (en) 2020-06-19 2021-12-23 Takayoshi Tanaka Anti-t cell antigen-binding molecule for use in combination with angiogenesis inhibitor
EP4168447A1 (en) 2020-06-19 2023-04-26 F. Hoffmann-La Roche AG Antibodies binding to cd3 and cd19
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
CN115734972A (zh) 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗cd73抗体及其用途
EP4168443A1 (en) 2020-06-22 2023-04-26 Almirall S.A. Anti-il-36 antibodies and methods of use thereof
JP2023533217A (ja) 2020-06-24 2023-08-02 ジェネンテック， インコーポレイテッド アポトーシス耐性細胞株
US20250262293A1 (en) 2020-07-07 2025-08-21 BioNTech SE Therapeutic rna for hpv-positive cancer
MX2023000339A (es) 2020-07-10 2023-02-09 Hoffmann La Roche Anticuerpos que se unen a celulas cancerosas y dirigen radionucleotidos a dichas celulas.
BR112023000839A2 (pt) 2020-07-17 2023-02-07 Genentech Inc Anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos para produzir um anticorpo que se liga a notch2 humano, para tratar um indivíduo com uma doença pulmonar muco-obstrutiva e para reduzir o número de células secretoras em um indivíduo, composição farmacêutica, anticorpo, anticorpo para uso e uso do anticorpo
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
KR20230133832A (ko) 2020-07-29 2023-09-19 다이내믹큐어 바이오테크놀로지 엘엘씨 항-cd93 구축물 및 그의 용도
JP2023536602A (ja) 2020-08-03 2023-08-28 ジェネンテック， インコーポレイテッド リンパ腫のための診断及び治療方法
EP4192868A1 (en) 2020-08-05 2023-06-14 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
BR112023002123A2 (pt) 2020-08-07 2023-03-07 Genentech Inc Proteína de fusão fc, ácidos nucleicos isolados, método de produção da proteína de fusão fc, formulação farmacêutica, métodos para expandir o número de células dendríticas (dcs) em um indivíduo e para tratar um câncer, proteína fc sem efetora e anticorpo
CN111759732B (zh) * 2020-08-12 2024-12-06 河南省人民医院 一种用于外周血造血干细胞冻存的多通道连接管路及方法
JP2023537761A (ja) 2020-08-14 2023-09-05 エイシー イミューン ソシエテ アノニム ヒト化抗ｔｄｐ－４３結合分子およびその使用
CA3190803A1 (en) 2020-08-14 2022-02-17 F. Hoffmann-La Roche Ag Methods for treating multiple sclerosis with ocrelizumab
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
TW202227625A (zh) 2020-08-28 2022-07-16 美商建南德克公司 宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
MX2023002496A (es) 2020-09-04 2023-03-09 Hoffmann La Roche Anticuerpo que se une al factor de crecimiento endotelial vascular a (vegf-a) y a la angiopoyetina 2 (ang2) y metodos de uso.
AU2021341526A1 (en) 2020-09-14 2023-04-27 IGI Therapeutics SA Antibodies that bind to il1rap and uses thereof
MX2023002984A (es) 2020-09-15 2023-04-10 Bayer Ag Nuevos anticuerpos anti-a2ap y usos de los mismos.
WO2022063262A1 (en) 2020-09-28 2022-03-31 Angitia Biopharmaceuticals Guangzhou Limited Anti-sclerostin constructs and uses thereof
KR20230104611A (ko) 2020-09-30 2023-07-10 드렌 바이오, 인크. 항-cd94 항체 및 이의 사용 방법
JP2023544407A (ja) 2020-10-05 2023-10-23 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
US12037399B2 (en) 2020-10-07 2024-07-16 Dren Bio, Inc. Anti-Dectin-1 antibodies and methods of use thereof
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
AR123855A1 (es) 2020-10-20 2023-01-18 Genentech Inc Anticuerpos anti-mertk conjugados con peg y métodos de uso
AU2021366287A1 (en) 2020-10-20 2023-04-13 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to Gremlin-1 and uses thereof
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
IL302217A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates
IL302400A (en) 2020-11-04 2023-06-01 Genentech Inc Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
MX2023005132A (es) 2020-11-04 2023-05-25 Genentech Inc Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
WO2022104150A1 (en) 2020-11-12 2022-05-19 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
KR20230113581A (ko) 2020-11-25 2023-07-31 실리오 디벨럽먼트, 인크. 종양 특이적 절단성 링커
AR125581A1 (es) 2020-12-07 2023-08-02 UCB Biopharma SRL Anticuerpos multiespecíficos y combinaciones de anticuerpos
CN116802211A (zh) 2020-12-07 2023-09-22 Ucb生物制药有限责任公司 针对白介素-22的抗体
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
IL303656A (en) 2020-12-17 2023-08-01 Hoffmann La Roche Anti-hla-g antibodies and use thereof
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CN117098548A (zh) 2020-12-23 2023-11-21 信达生物制药(苏州)有限公司 抗b7-h3抗体及其用途
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
AU2022206061A1 (en) 2021-01-06 2023-07-06 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
WO2022152656A1 (en) 2021-01-12 2022-07-21 F. Hoffmann-La Roche Ag Split antibodies which bind to cancer cells and target radionuclides to said cells
AU2022207624A1 (en) 2021-01-13 2023-07-13 F. Hoffmann-La Roche Ag Combination therapy
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
AU2022212599A1 (en) 2021-01-28 2023-08-17 Universität Ulm Method and means for modulating b-cell mediated immune responses
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
EP4288458A1 (en) 2021-02-03 2023-12-13 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
CA3209136A1 (en) 2021-02-09 2022-08-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
AU2022220611A1 (en) 2021-02-09 2023-08-24 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
US20240226295A9 (en) 2021-02-15 2024-07-11 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
CN117157317A (zh) 2021-02-26 2023-12-01 拜耳公司 用于治疗异常子宫出血的IL-11或IL-11Ra的抑制剂
EP4301467A1 (en) 2021-03-01 2024-01-10 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
CN116917325A (zh) 2021-03-01 2023-10-20 西里欧发展公司 用于治疗癌症的被掩蔽的ctla4和pd1/pdl1抗体的组合
JP2024509169A (ja) 2021-03-03 2024-02-29 ソレント・セラピューティクス・インコーポレイテッド 抗ｂｃｍａ抗体を含む抗体－薬物コンジュゲート
TW202302646A (zh) 2021-03-05 2023-01-16 美商當康生物科技有限公司 抗vista構築體及其用途
US20240392004A1 (en) 2021-03-10 2024-11-28 Immunowake Inc. Immunomodulatory molecules and uses thereof
JP2024512377A (ja) 2021-03-12 2024-03-19 ジェネンテック， インコーポレイテッド 抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
CA3213599A1 (en) 2021-03-15 2022-09-22 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
TW202300648A (zh) 2021-03-25 2023-01-01 美商當康生物科技有限公司 抗-igfbp7構築體及其用途
PE20240357A1 (es) 2021-03-30 2024-02-27 Bayer Ag Anticuerpos anti-sema3a y usos de los mismos
JP7717832B2 (ja) 2021-04-10 2025-08-04 ジェンマブ エー／エス Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
CA3215965A1 (en) 2021-04-19 2022-10-27 Amy Shen Modified mammalian cells
JP2024514281A (ja) 2021-04-23 2024-04-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｎｋ細胞係合剤関連の有害作用の防止または軽減
US20250066490A1 (en) 2021-04-23 2025-02-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
WO2022228706A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2024516305A (ja) 2021-05-03 2024-04-12 ユーシービー バイオファルマ エスアールエル 抗体
WO2022236335A1 (en) 2021-05-07 2022-11-10 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
MX2023012703A (es) 2021-05-07 2023-11-21 Viela Bio Inc Uso de un anticuerpo de cumulo de diferenciacion 19 (anti-cd19) para tratar la miastenia grave.
IL308351A (en) 2021-05-12 2024-01-01 Genentech Inc Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
EP4337317A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2
IL308417A (en) 2021-05-14 2024-01-01 Genentech Inc Methods for the treatment of CD20-positive proliferative disorder with musuntozumab and folatuzumab and dotin
WO2022243347A1 (en) * 2021-05-18 2022-11-24 Christian-Albrechts-Universität Zu Kiel Co-stimulatory multispecific antibodies
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
WO2022246259A1 (en) 2021-05-21 2022-11-24 Genentech, Inc. Modified cells for the production of a recombinant product of interest
EP4155321A1 (en) 2021-06-04 2023-03-29 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
EP4351582B1 (en) 2021-06-09 2025-10-08 F. Hoffmann-La Roche AG Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
WO2022262808A1 (en) * 2021-06-16 2022-12-22 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd20 genes
WO2022266660A1 (en) 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
JP2024525188A (ja) 2021-06-18 2024-07-10 セリーニ バイオ インコーポレイテッド ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法
CR20240026A (es) 2021-06-25 2024-03-14 Chugai Pharmaceutical Co Ltd Anticuerpo anti-ctla-4
TWI879694B (zh) 2021-06-25 2025-04-01 日商中外製藥股份有限公司 抗ctla-4抗體的用途
IL309071A (en) 2021-07-02 2024-02-01 Genentech Inc Methods and compositions for the treatment of cancer
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
TW202317633A (zh) 2021-07-08 2023-05-01 美商舒泰神（加州）生物科技有限公司 特異性識別ｔｎｆｒ２的抗體及其用途
EP4370545A1 (en) 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding
US20240327544A1 (en) 2021-07-13 2024-10-03 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023284714A1 (zh) 2021-07-14 2023-01-19 舒泰神（北京）生物制药股份有限公司 特异性识别cd40的抗体及其应用
JP2024527606A (ja) 2021-07-14 2024-07-25 ジェネンテック， インコーポレイテッド 抗ｃ－ｃモチーフケモカイン受容体８（ｃｃｒ８）抗体及び使用方法
CN117730102A (zh) 2021-07-22 2024-03-19 豪夫迈·罗氏有限公司 异二聚体Fc结构域抗体
JP2024526880A (ja) 2021-07-22 2024-07-19 ジェネンテック， インコーポレイテッド 脳標的化組成物及びその使用方法
CN117715936A (zh) 2021-07-28 2024-03-15 豪夫迈·罗氏有限公司 用于治疗癌症的方法和组合物
MX2024001415A (es) 2021-07-30 2024-02-27 Ona Therapeutics S L Anticuerpos anti-cd36 y su uso para tratar el cancer.
CN117897404A (zh) 2021-08-02 2024-04-16 信达生物制药(苏州)有限公司 抗CD79b×CD3双特异性抗体及其用途
JP2024528217A (ja) 2021-08-03 2024-07-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗体および使用方法
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2023019239A1 (en) 2021-08-13 2023-02-16 Genentech, Inc. Dosing for anti-tryptase antibodies
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
JP2024534067A (ja) 2021-08-19 2024-09-18 エフ． ホフマン－ラ ロシュ アーゲー 多価抗バリアントｆｃ領域抗体および使用方法
AU2022332285A1 (en) 2021-08-23 2024-02-15 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
JP2024534853A (ja) 2021-08-30 2024-09-26 ジェネンテック， インコーポレイテッド 抗ポリビキチン多重特異性抗体
KR20240058167A (ko) 2021-09-17 2024-05-03 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Sars-cov-2 중화 항체 동정을 위한 합성 인간화 라마 나노바디 라이브러리 및 이의 용도
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
TW202323810A (zh) 2021-10-08 2023-06-16 日商中外製藥股份有限公司 預填充式注射器製劑的調製方法
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
AU2022379952A1 (en) 2021-11-05 2024-05-16 Mab Biotec, Inc. Monoclonal antibodies against carcinoembryonic antigens, and their uses
JP2024544885A (ja) 2021-11-10 2024-12-05 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
AU2022389969A1 (en) 2021-11-16 2024-05-02 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
CA3235206A1 (en) 2021-11-16 2023-05-25 Davide BASCO Novel molecules for therapy and diagnosis
EP4437006A1 (en) 2021-11-26 2024-10-02 F. Hoffmann-La Roche AG Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
US20250066458A1 (en) 2021-12-06 2025-02-27 Beijing Solobio Genetechnology Co., Ltd. Bispecific Antibodies Specifically Binding to Klebsiella Pneumoniae O2 Antigen and O1 Antigen and Compositions Thereof
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
WO2023114829A1 (en) 2021-12-15 2023-06-22 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
EP4448579A1 (en) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies and methods of use
WO2023109900A1 (en) 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
TW202337904A (zh) 2022-01-07 2023-10-01 美商壯生和壯生企業創新公司 ＩＬ－１β結合蛋白之材料及方法
WO2023141445A1 (en) 2022-01-19 2023-07-27 Genentech, Inc. Anti-notch2 antibodies and conjugates and methods of use
EP4476259A1 (en) * 2022-02-08 2024-12-18 Amgen Inc. Codon-optimized nucleic acids encoding ocrelizumab
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
AU2023221539A1 (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
MA67298A1 (fr) 2022-02-18 2025-03-28 Rakuten Medical, Inc. Molécules d'anticorps anti-ligand de mort cellulaire programmée 1 (pd-l1), polynucléotides de codage et méthodes d'utilisation
US20250243260A1 (en) 2022-03-07 2025-07-31 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
JP2025509286A (ja) 2022-03-10 2025-04-11 ビバソル， インコーポレイテッド 抗体－薬物コンジュゲートおよびその使用
JP2025509824A (ja) 2022-03-18 2025-04-11 イボルブイミューン セラピューティクス， インコーポレイテッド 二特異性抗体融合分子及びその使用方法
EP4496631A1 (en) 2022-03-23 2025-01-29 F. Hoffmann-La Roche AG Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
JP2025514610A (ja) 2022-03-25 2025-05-09 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｍｓｌｎ抗体及び使用方法
WO2023192827A1 (en) 2022-03-26 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies to hiv-1 env and their use
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
EP4504780A1 (en) 2022-04-01 2025-02-12 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4504775A1 (en) 2022-04-08 2025-02-12 AC Immune SA Anti-tdp-43 binding molecules
CN119384432A (zh) 2022-04-13 2025-01-28 基因泰克公司 治疗性蛋白质的药物组合物和使用方法
KR20250004776A (ko) 2022-04-13 2025-01-08 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법
WO2023203177A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
KR20250006932A (ko) 2022-05-03 2025-01-13 제넨테크, 인크. 항-Ly6E 항체, 면역접합체 및 이들의 용도
CN119487065A (zh) 2022-05-09 2025-02-18 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
AR129268A1 (es) 2022-05-11 2024-08-07 Hoffmann La Roche Anticuerpo que se une a vegf-a e il6 y métodos de uso
JP2025517650A (ja) 2022-05-11 2025-06-10 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
WO2023237706A2 (en) 2022-06-08 2023-12-14 Institute For Research In Biomedicine (Irb) Cross-specific antibodies, uses and methods for discovery thereof
EP4536290A1 (en) 2022-06-08 2025-04-16 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
TW202417042A (zh) 2022-07-13 2024-05-01 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
IL318252A (en) 2022-07-19 2025-03-01 Genentech Inc Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
WO2024020407A1 (en) 2022-07-19 2024-01-25 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
EP4558528A1 (en) 2022-07-22 2025-05-28 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
EP4565329A1 (en) 2022-08-01 2025-06-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
MA71684A (fr) 2022-08-05 2025-05-30 Janssen Biotech, Inc. Protéines de liaison de récepteur de transferrine pour traitement de tumeurs cérébrales
MA71685A (fr) 2022-08-05 2025-05-30 Janssen Biotech, Inc. Constructions de liaison à cd98 pour le traitement de tumeurs cérébrales
CN119698274A (zh) 2022-08-19 2025-03-25 亿一生物医药开发(上海)有限公司 包含g-csf的制剂及其用途
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
JP2025529903A (ja) 2022-08-26 2025-09-09 ジュノー セラピューティクス インコーポレイテッド デルタ様リガンド３（ｄｌｌ３）に特異的な抗体およびキメラ抗原受容体
CN120153254A (zh) 2022-09-01 2025-06-13 基因泰克公司 膀胱癌的治疗和诊断方法
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2024067344A1 (zh) 2022-09-27 2024-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein
EP4598959A1 (en) 2022-10-07 2025-08-13 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
AU2023365967A1 (en) 2022-10-20 2025-06-05 Beijing Solobio Genetechnology Co., Ltd. Antibody combination specifically binding to trail or fasl, and bispecific antibody
TW202426505A (zh) 2022-10-25 2024-07-01 美商建南德克公司 癌症之治療及診斷方法
CN120152989A (zh) 2022-11-03 2025-06-13 豪夫迈·罗氏有限公司 抗cd19/抗cd28双特异性抗体的组合疗法
KR20250099702A (ko) 2022-11-04 2025-07-02 길리애드 사이언시즈, 인코포레이티드 항-ccr8 항체, 화학요법 및 면역요법 조합을 사용하는 항암 요법
JP2025537197A (ja) 2022-11-08 2025-11-14 ジェネンテック， インコーポレイテッド 小児期発症特発性ネフローゼ症候群を治療するための組成物および方法
IL320220A (en) 2022-11-09 2025-06-01 Cis Biopharma Ag Antibodies against L1-CAM and their uses for diagnostic and therapeutic applications
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024108053A1 (en) 2022-11-17 2024-05-23 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
KR20250111141A (ko) 2022-11-25 2025-07-22 추가이 세이야쿠 가부시키가이샤 단백질의 제조 방법
EP4631974A1 (en) 2022-12-08 2025-10-15 Nanjing Vazyme Biotech Co., Ltd. Antibody specifically binding to rsv
AU2023393653A1 (en) 2022-12-14 2025-05-22 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024137381A1 (en) 2022-12-19 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies for treating sars-cov-2 infection
WO2024145398A1 (en) 2022-12-27 2024-07-04 Yale University Antibody drug conjugates
AR131638A1 (es) 2023-01-18 2025-04-16 Genentech Inc Anticuerpos multiespecíficos y usos de estos
EP4655007A1 (en) 2023-01-23 2025-12-03 Yale University Antibody oligonucleotide conjugates
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
TW202436339A (zh) 2023-01-31 2024-09-16 瑞士商赫孚孟拉羅股份公司 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
WO2024173607A2 (en) 2023-02-14 2024-08-22 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
CN120712282A (zh) 2023-02-17 2025-09-26 阿布林克斯有限公司 结合新生儿fc受体的多肽
CN120917043A (zh) 2023-03-08 2025-11-07 Ac免疫有限公司 抗tdp-43结合分子及其用途
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
US20240327522A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
AU2024251934A1 (en) 2023-04-12 2025-10-30 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AR132623A1 (es) 2023-05-08 2025-07-16 Hoffmann La Roche PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
WO2024238537A1 (en) 2023-05-16 2024-11-21 F. Hoffmann-La Roche Ag Pd-1 -regulated il-2 immunocytokine and uses thereof
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
WO2024243355A1 (en) 2023-05-24 2024-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
WO2024246356A1 (en) 2023-06-01 2024-12-05 Pierre Fabre Medicament Silenced antibody-based anti-met constructs for the treatment of tumors and metastasis
TW202504641A (zh) 2023-06-08 2025-02-01 美商建南德克公司 用於淋巴瘤之診斷及治療方法的巨噬細胞特徵
TW202502809A (zh) 2023-06-22 2025-01-16 美商建南德克公司 抗體及其用途
WO2024263845A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Treatment of multiple myeloma
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025002410A1 (en) 2023-06-30 2025-01-02 Evive Biotechnology (Shanghai) Ltd G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
TW202517294A (zh) 2023-07-11 2025-05-01 美商建南德克公司 用於治療多發性硬化症之組成物及方法
WO2025024233A1 (en) 2023-07-21 2025-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies that broadly target coronaviruses
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025038492A1 (en) 2023-08-11 2025-02-20 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025045251A2 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Multispecific constructs comprising anti-factor d moiety
TW202525856A (zh) 2023-09-08 2025-07-01 美商Ｍｌａｂ生物科學有限公司 雙功能性蛋白質及其用途
WO2025059037A1 (en) 2023-09-11 2025-03-20 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
WO2025064539A1 (en) 2023-09-19 2025-03-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Herv-e antibodies and methods of their use
WO2025064890A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025064885A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
TW202517673A (zh) 2023-09-25 2025-05-01 瑞士商赫孚孟拉羅股份公司 與Ｃ３ｂＢｂ結合之抗體
US20250115680A1 (en) 2023-09-26 2025-04-10 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
TW202517674A (zh) 2023-10-19 2025-05-01 德商拜耳廠股份有限公司 抗gpc3抗體及其放射性結合物
WO2025099120A1 (en) 2023-11-09 2025-05-15 F. Hoffmann-La Roche Ag Multispecific antibodies with conditional activity
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025111402A1 (en) 2023-11-21 2025-05-30 Board Of Regents Of The University Of Nebraska Anti-amyloid beta antibodies and related compositions and methods thereof
WO2025117639A1 (en) 2023-11-27 2025-06-05 Profoundbio Us Co. Antibodies and methods for ptk7 detection
WO2025117516A1 (en) 2023-11-30 2025-06-05 Genzyme Corporation Methods for treating cd20-related disorders
WO2025117384A1 (en) 2023-12-01 2025-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing influenza hemagglutinin stem-directed antibodies
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025125118A1 (en) 2023-12-11 2025-06-19 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025137410A1 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine
WO2025137523A2 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical formulations of antibodies that bind interleukin 13
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
WO2025137284A2 (en) 2023-12-21 2025-06-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants
WO2025133290A1 (en) 2023-12-21 2025-06-26 Temper Bio Protein for immune regulation
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
WO2025179281A1 (en) 2024-02-23 2025-08-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of cardiovascular disease with antxr1 antibodies
WO2025184416A1 (en) 2024-02-27 2025-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single-domain antibodies and bispecific antibodies against hiv-1 and their use
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025186332A1 (en) 2024-03-05 2025-09-12 Ac Immune Sa Vectorized anti-tdp-43 antibodies
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
WO2025196639A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody-drug conjugates, and uses thereof
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
WO2025215124A2 (en) 2024-04-12 2025-10-16 F. Hoffmann-La Roche Ag Combination treatment of glofitamab and chemotherapy
WO2025222129A2 (en) 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers
WO2025233266A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd39 blocking agents in combination with anti-cd20 x cd3 t cell engagers
WO2025238187A1 (en) 2024-05-15 2025-11-20 Cis Biopharma Ag Immunoconjugates targeting l1-cam
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002128A (en) * 1934-02-19 1935-05-21 Ray A Reidenbaugh Display rack
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
FI891226A7 (fi) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
KR920700674A (ko) 1989-03-21 1992-08-10 원본미기재 특정 t세포 집단에 의한 발명 반응으로부터 야기되는 질병에 대한 예방접종 및 방법
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
JP3072330B2 (ja) 1989-07-19 2000-07-31 ジ・イミューン・レスポンス・コーポレーション 自己免疫疾患および悪性疾患の治療のためのｔ細胞リセプターペプチド
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PL174721B1 (pl) * 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
AU8296098A (en) * 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
JP2001521909A (ja) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド 糖タンパク質グリコフォームを含む方法及び組成物
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2990054A1 (en) * 1998-08-11 2016-03-02 Biogen Inc. Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
DK2055313T3 (en) 1998-11-09 2015-07-27 Biogen Inc Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody
MXPA01004649A (es) 1998-11-09 2002-05-06 Idec Pharma Corp Tratamiento con anticuerpo quimerico anti-cd20 para pacientes que reciben transplantes de medula osea o celulas madre de sangre periferica.
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
EP1035172A3 (en) * 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
HK1043312B (en) 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
DK1194167T3 (da) 1999-06-09 2009-11-16 Immunomedics Inc Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer
ITMI991299A1 (it) * 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
CN1373672A (zh) 1999-07-12 2002-10-09 杰南技术公司 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
MXPA02001398A (es) 1999-08-11 2002-08-12 Idec Pharma Corp Tratamiento de pacientes que tienen linfoma no hodgkins con lesion de medula osea con anticuerpos anti-cd20.
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
JP2003513937A (ja) * 1999-11-08 2003-04-15 アイデック・ファーマシューティカルズ・コーポレイション 抗ｃｄ２０抗体および／または化学療法薬および放射線療法と併用して抗ｃｄ４０ｌ抗体を使用するｂ細胞悪性疾患の処置
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020009427A1 (en) * 2000-03-24 2002-01-24 Wolin Maurice J. Methods of therapy for non-hodgkin's lymphoma
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
KR20020091170A (ko) 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
LT2857516T (lt) * 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
JP2003531178A (ja) * 2000-04-25 2003-10-21 アイデック ファーマスーティカルズ コーポレイション 中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与
CA2411102A1 (en) 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
JP2003535907A (ja) * 2000-06-22 2003-12-02 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
MXPA03000306A (es) 2000-07-12 2004-04-05 Idec Pharma Corp Tratamiento de malignidades de celulas b que usan una combinacion de anticuerpos supresores de celulas b y aplicaciones relacionadas con anticuerpos moduladores inmunes.
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
AU2002213357A1 (en) * 2000-10-20 2002-05-06 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
KR20100031769A (ko) * 2000-12-28 2010-03-24 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
AU2002240120B2 (en) 2001-01-29 2008-05-08 Biogen Idec Inc. Modified antibodies and methods of use
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
US20020197256A1 (en) * 2001-04-02 2002-12-26 Genentech, Inc. Combination therapy
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
JP2005515161A (ja) 2001-06-14 2005-05-26 インターミューン インコーポレイテッド γ−インターフェロンおよびＢ細胞特異的抗体の併用療法
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
AU2002327037A1 (en) * 2001-09-20 2003-04-01 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
DK1443961T3 (da) * 2001-10-25 2009-08-24 Genentech Inc Glycoprotein-sammensætninger
US7127096B2 (en) * 2001-11-20 2006-10-24 Accuimage Diagnostics Corp. Method and software for improving coronary calcium scoring consistency
JP2005538034A (ja) 2001-12-07 2005-12-15 カイロン コーポレイション 非ホジキンリンパ腫の治療方法
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1519959B1 (en) * 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219818A1 (en) * 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
ES2524694T3 (es) 2002-10-17 2014-12-11 Genmab A/S Anticuerpos monoclonales humanos contra CD20
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
PT1613350E (pt) * 2003-04-09 2009-06-24 Genentech Inc Terapia de doença auto-imune num paciente com uma resposta inadequada a um inibidor de tnf-alfa
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
AR049200A1 (es) 2004-06-04 2006-07-05 Genentech Inc Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
JP2008545958A (ja) * 2005-05-20 2008-12-18 ジェネンテック・インコーポレーテッド 自己免疫性疾患の被検体の生体試料の前処理
US8144978B2 (en) * 2007-08-01 2012-03-27 Tandent Vision Science, Inc. System and method for identifying complex tokens in an image
KR101041914B1 (ko) * 2008-06-26 2011-06-15 부산대학교 산학협력단 셀레늄에 의해 탈분화된 세포, 이의 제조방법 및 이의 용도
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法

Also Published As

Publication number Publication date
HUP0500954A2 (en) 2007-09-28
EP2301966A1 (en) 2011-03-30
EP1572744B1 (en) 2010-06-09
TWI335821B (en) 2011-01-11
JP2012044997A (ja) 2012-03-08
JP4351674B2 (ja) 2009-10-28
CN103833854A (zh) 2014-06-04
ES2347241T3 (es) 2010-10-27
FR18C1023I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-07-13
CR11367A (es) 2010-07-23
SI2289936T1 (sl) 2017-10-30
BRPI0316779B1 (pt) 2020-04-28
SG2013036975A (en) 2016-07-28
RS20100366A (sr) 2011-04-30
KR20070055625A (ko) 2007-05-30
HUE035898T2 (en) 2018-05-28
EP1572744A2 (en) 2005-09-14
WO2004056312A2 (en) 2004-07-08
IL214083A0 (en) 2011-08-31
HK1248731A1 (en) 2018-10-19
CY2018009I1 (el) 2018-06-27
JP2006517399A (ja) 2006-07-27
HK1074208A1 (en) 2005-11-04
RU2005122448A (ru) 2006-03-20
CY2018009I2 (el) 2018-06-27
EP2289936A1 (en) 2011-03-02
RU2326127C2 (ru) 2008-06-10
PL377328A1 (pl) 2006-01-23
US20140154242A1 (en) 2014-06-05
US8562992B2 (en) 2013-10-22
US20060024300A1 (en) 2006-02-02
HU227217B1 (en) 2010-11-29
BR0316779A (pt) 2005-11-01
BE2018C021I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2023-03-07
ATE470675T1 (de) 2010-06-15
PT1572744E (pt) 2010-09-07
JP2009159950A (ja) 2009-07-23
UA89350C2 (uk) 2010-01-25
US20190071511A1 (en) 2019-03-07
PL212899B1 (pl) 2012-12-31
WO2004056312A3 (en) 2005-05-26
AR093046A2 (es) 2015-05-13
US20060034835A1 (en) 2006-02-16
CN103833854B (zh) 2017-12-12
EP1572744A4 (en) 2006-07-12
MXPA05006511A (es) 2006-02-17
US20170158773A1 (en) 2017-06-08
CY1110759T1 (el) 2015-06-10
NZ566907A (en) 2009-10-30
AR042485A1 (es) 2005-06-22
EP1944320A1 (en) 2008-07-16
ES2633311T3 (es) 2017-09-20
AU2003301079B2 (en) 2011-06-23
KR100910433B1 (ko) 2009-08-04
DE60332957D1 (de) 2010-07-22
MA27704A1 (fr) 2006-01-02
SI1572744T1 (sl) 2010-09-30
NO20053435L (no) 2005-08-31
TW200501982A (en) 2005-01-16
KR20050086913A (ko) 2005-08-30
FR18C1023I2 (fr) 2019-05-17
CL2008003323A1 (es) 2009-03-06
NO338402B1 (no) 2016-08-15
US7799900B2 (en) 2010-09-21
JP5885457B2 (ja) 2016-03-15
TW201000132A (en) 2010-01-01
US20090155257A1 (en) 2009-06-18
AU2003301079A1 (en) 2004-07-14
CA2507898A1 (en) 2004-07-08
HRP20050649A2 (en) 2005-12-31
DK2289936T3 (en) 2017-07-31
EP2289936B1 (en) 2017-05-31
BRPI0316779B8 (pt) 2023-02-28
IL168754A (en) 2011-09-27
AU2003301079C1 (en) 2018-03-08
HUS1800030I1 (hu) 2018-07-30
AR072523A2 (es) 2010-09-01
CA2507898C (en) 2014-02-18
HRP20050649B1 (hr) 2016-06-17
RS20050467A (sr) 2007-08-03
CR7875A (es) 2008-11-07
EP3263596A1 (en) 2018-01-03
DK1572744T3 (da) 2010-09-20
US20220002430A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
US20220002430A1 (en) Immunoglobulin variants and uses thereof
NO20150245L (no) Immunoglobulinvarianter og anvendelser derav
AU2011226858B2 (en) Immunoglobulin variants and uses thereof
HK1156047A (en) Immunoglobulin variants and uses thereof
HK1120058A (en) Immunoglobulin variants and uses thereof
HK1074208B (en) Immunoglobulin variants and uses thereof
HK1154871A (en) Immunoglobulin variants and uses thereof
HK1129406A (zh) 免疫球蛋白變體及其用途
HK1129406B (en) Immunoglobulin variants and uses thereof
HK1154871B (en) Immunoglobulin variants and uses thereof
HK1129405A (en) Immunoglobulin variants and uses thereof
HK1129407A (en) Immunoglobulin variants and uses thereof